Fibrate-associated adverse effects beyond muscle and liver toxicity

dc.contributor.authorFlorentin, M.en
dc.contributor.authorLiberopoulos, E. N.en
dc.contributor.authorMikhailidis, D. P.en
dc.contributor.authorElisaf, M. S.en
dc.date.accessioned2015-11-24T19:15:52Z
dc.date.available2015-11-24T19:15:52Z
dc.identifier.issn1873-4286-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/21574
dc.rightsDefault Licence-
dc.subjectAnimalsen
dc.subjectClinical Trials as Topic/methodsen
dc.subjectClofibric Acid/*adverse effects/chemistryen
dc.subject*Drug-Induced Liver Injuryen
dc.subjectHumansen
dc.subjectLiver Diseases/epidemiology/pathologyen
dc.subjectMuscle, Skeletal/*drug effects/pathologyen
dc.subjectMuscular Diseases/*chemically induced/epidemiology/pathologyen
dc.titleFibrate-associated adverse effects beyond muscle and liver toxicityen
heal.abstractFibrate derivatives have a 40-year history in the management of dyslipidemia. Although this class of drugs is generally well tolerated, several safety issues have arisen from their use. In the present article we review the literature describing side effects associated with the use of fibrates except for those that are liver and muscle related. These effects are less well known but are clinically relevant.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/18336300-
heal.journalNameCurr Pharm Desen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2008-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Φόρτωση...
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή: